Compare DAO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | AGIO |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2019 | 2013 |
| Metric | DAO | AGIO |
|---|---|---|
| Price | $14.66 | $32.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.88 |
| AVG Volume (30 Days) | 63.2K | ★ 736.0K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $12.24 | $76.75 |
| Revenue Next Year | $14.60 | $170.73 |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $22.24 |
| 52 Week High | $18.94 | $46.00 |
| Indicator | DAO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 44.44 |
| Support Level | $9.57 | $32.43 |
| Resistance Level | $18.79 | $35.88 |
| Average True Range (ATR) | 0.67 | 1.37 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 68.69 | 33.46 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.